Antibody-drug conjugates: a practical review on clinical management of toxicities [0.03%]
抗体-药物偶联物毒性的临床管理实践综述
Antonio De Palma,Marco Marenco,Sofia Mancini et al.
Antonio De Palma et al.
Introduction: Antibody - drug conjugates (ADCs) are rapidly expanding across solid tumors, but their toxicity profiles remain heterogeneous and clinically challenging. This review addresses the need for practical, standar...
Polypharmacy, polypharmacology, and polypharmacotherapy: clarifying definitions and complementary roles in cancer treatment - a narrative review [0.03%]
从癌症治疗的角度阐明多药疗法、多重药物机制作用和多种药物治疗的定义及互补作用-叙述性综述
Aurora Gonzalez-Fierro,Alma Chavez-Blanco,Guadalupe Dominguez-Gomez et al.
Aurora Gonzalez-Fierro et al.
Introduction: Cancer treatment is predominantly guided by the Somatic Mutation Theory (SMT), which focuses on highly selective drugs targeting driver mutations. This approach has transformed outcomes in specific cancers, ...
Predictors of warfarin therapeutic dose in cancer patients: a preliminary comparative study using machine learning-integrated explainable artificial intelligence and Bayesian models [0.03%]
基于机器学习和贝叶斯模型的集成可解释人工智能预测癌症患者华法林治疗剂量的影响因素：初步比较研究
Kannan Sridharan,Gowri Sivaramakrishnan,Matteo Santoni
Kannan Sridharan
Background: Warfarin dosing in cancer patients is challenging due to altered pathophysiology and variable responses. While machine learning offers predictive potential, clinical adoption requires interpretability. This st...
A nephrology perspective on the clinical impact and management of delayed high-dose methotrexate elimination [0.03%]
肾病学视角下的高剂量甲氨蝶呤延迟排出的临床影响及处理方法
María José Soler,Laura Cosmai,Lui Forni et al.
María José Soler et al.
Introduction: Delayed methotrexate elimination (DME) is observed in ~15% of treatment cycles in patients with cancer receiving high-dose methotrexate (HDMTX). Given the strong association between DME and nephrotoxicity, o...
Lymphovascular invasion in bladder cancer: from prognostic marker toward a clinical priority [0.03%]
膀胱癌的淋巴管侵犯：从预后标记物到临床优先事项
Daniel-Vasile Dulf,AntonioDe Leo,Camelia Alexandra Coadă
Daniel-Vasile Dulf
Emerging immune checkpoint inhibitor strategies in cervical cancer: a scoping review of ongoing clinical trials [0.03%]
宫颈癌中新兴的免疫检查点抑制剂策略：正在进行中的临床试验综述
Karolina Górniak,Radosław Łupkowski,Mirosława Püsküllüoglu et al.
Karolina Górniak et al.
Introduction: Immunotherapy with immune checkpoint inhibitors (ICIs) has become an important component of cervical cancer treatment, leading to improved outcomes in selected patient populations. However, despite recent ap...
Waseem Jerjes
Waseem Jerjes
Real-world treatment patterns and survival in advanced/metastatic triple-negative breast cancer in Japan [0.03%]
日本晚期/转移性三阴性乳腺癌的治疗模式和生存分析研究
Hitomi Sanno,Yuichiro Ito,Kazuko Taniguchi et al.
Hitomi Sanno et al.
Aims: To gather information regarding treatment patterns, outcomes, and healthcare resource utilization (HCRU) for patients with advanced/metastatic triple-negative breast cancer (TNBC) in real-world clinical settings in ...
Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state-of-the-art [0.03%]
肌层浸润性膀胱癌保膀胱综合治疗的现状及展望
Catherine Fahey,Shivani Sud,Anvitha Remella et al.
Catherine Fahey et al.
Introduction: Despite major advances in the management of bladder cancer over the past decade, including practice-changing studies with immune checkpoint inhibitors and antibody drug conjugates (ADC), patients continue to...
Complications following small-molecule inhibitors for non-small cell lung cancer [0.03%]
非小细胞肺癌小分子靶向药物的不良反应及处理措施
Caroline Kamali,Simon Ekman
Caroline Kamali
Introduction: Targeted therapies for oncogene-driven non-small cell lung cancer (NSCLC) have transformed precision oncology by enabling treatment tailored to specific molecular alterations and substantially improving outc...